# Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

> **NCT04020263** · PHASE3 · RECRUITING · sponsor: **Pr Bruno LEVY** · enrollment: 610 (estimated)

## Conditions studied

- Cardiogenic Shock

## Interventions

- **DRUG:** Levosimendan 2.5 MG/ML Injectable Solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04020263
- **Lead sponsor:** Pr Bruno LEVY
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-03
- **Primary completion:** 2027-02-03
- **Final completion:** 2028-01-03
- **Target enrollment:** 610 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04020263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04020263, "Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04020263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*